Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Fulcrum Therapeutics reports promising data and financial stability in Q4

Fulcrum Therapeutics showcased positive data for FTX-6058 and financial stability in their Q4 2022 earnings call
While facing challenges with the clinical hold, the company's strong cash position and promising programs offer opportunities for growth

Fulcrum Therapeutics reports solid financials, FDA challenges, and leadership change

Fulcrum Therapeutics navigates a mixed landscape with strong financials, promising clinical trial progress, and regulatory challenges that require careful resolution.
New leadership, ongoing FDA collaborations, and a robust cash position position Fulcrum for continued growth and innovation in the biopharmaceutical space.

Fulcrum Therapeutics reports stable finances, regulatory hurdles ahead

Fulcrum Therapeutics maintains a stable financial position with a focus on advancing key pipeline candidates.
Challenges include regulatory uncertainties for FTX-6058 and ongoing R&D investment impacting financials.
Opportunities lie in upcoming data releases, resolving regulatory issues, and strategic growth initiatives.

Fulcrum Therapeutics reports Q3 loss, progresses key clinical trials

Fulcrum Therapeutics reported a mixed performance in Q3 2023, with a net loss driven by significant R&D and administrative expenses.
Despite challenges in cash burn and timeline for commercialization, the company's strong cash position and promising clinical developments highlight its potential.
Opportunities lie in advancing regulatory filings, leveraging positive clinical results, and exploring additional endpoints to showcase therapy efficacy.

Fulcrum Therapeutics advances Phase III trials, secures strong financial position

Fulcrum Therapeutics made significant progress in advancing its pipeline with successful trial enrollments and resolution of clinical holds.
Financially, the company ended 2023 on a strong note with a healthy cash position and reported financials.
Challenges lie in meeting trial endpoints and managing expenses, but opportunities exist in market reception and further data collection.
Overall, Fulcrum's proactive approach to clinical development and stakeholder engagement positions it well for future growth.

Fulcrum Therapeutics secures Sanofi collaboration, advances Phase III trials

Fulcrum Therapeutics' collaboration with Sanofi and strong financial position provide a solid foundation for future growth and development.
The company's focus on advancing Phase III trials, addressing unmet medical needs, and driving innovation through novel endpoints positions it well for success.
While facing challenges in various operational aspects, Fulcrum's strategic planning and emphasis on key appointments and market access strategies indicate a proactive approach to overcoming obstacles.

Fulcrum Therapeutics reports strong Q2 earnings and advances clinical assets

Fulcrum Therapeutics achieved a significant turnaround in financial performance with a notable increase in net income and a strong cash position, supported by collaboration revenue.
Progress in Phase III trials for losmapimod and pociredir, along with positive patient engagement, bodes well for future drug development and market potential.
While facing regulatory and competitive challenges, the company's strategic collaborations, financial stability, and ongoing trials present opportunities for growth and market expansion.

Fulcrum Therapeutics navigates workforce reduction, focuses on sickle cell treatment

Fulcrum Therapeutics faces challenges with workforce reduction and program suspension but remains focused on advancing pociredir for sickle cell disease treatment.
The company's financial position is strong, with a cash balance of $257.2 million and plans to manage cash burn effectively in 2025.
Management changes and analyst inquiries underscore the need for strategic decision-making and operational efficiency to drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fulcrum Therapeutics, Inc. (FULC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Fulcrum Therapeutics, Inc. (FULC): Can Its 20.6% Jump Turn into More Strength?

― FTX-6058 granted Fast Track Designation for sickle cell disease (SCD) from FDA in December 2022 ― ― Completed enrollment in 6 mg and 2 mg dose cohorts of the Phase 1b trial of FTX-6058 in SCD; enrollment ongoing in 12 mg dose cohort ― ― Additional FTX-6058 data from 6 mg cohort of ongoing Phase 1b trial show clinically relevant HbF increases of up to 9.5% ― ― Plan to complete enrollment in Phase 3 REACH trial of losmapimod in FSHD during 2H'23 ― Fulcrum announces CEO transition; Robert J. Gould, Ph.D., former president and founding chief executive officer of Fulcrum has been appointed as interim CEO as Bryan Stuart departs to pursue other opportunities ― ― Presentation at J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 4:30 p.m. PST/7:30 p.m. EST ―

Fulcrum Therapeutics Provides Business Update and 2023 Outlook

Robert J. Gould, Ph.D., former president and founding chief executive officer of Fulcrum, is appointed as interim CEO as Bryan Stuart departs to pursue other opportunities Robert J. Gould, Ph.D., former president and founding chief executive officer of Fulcrum, is appointed as interim CEO as Bryan Stuart departs to pursue other opportunities

Fulcrum Therapeutics Announces CEO Transition

The mean of analysts' price targets for Fulcrum Therapeutics, Inc. (FULC) points to a 232.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can Fulcrum Therapeutics, Inc. (FULC) Climb 232% to Reach the Level Wall Street Analysts Expect?

CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a virtual fireside chat at the 2022 BofA Securities Biotech SMID Cap Conference, on Thursday, December 8, 2022 at 9:10 a.m. ET

Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference

The consensus price target hints at a 232.3% upside potential for Fulcrum Therapeutics, Inc. (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Fulcrum Therapeutics, Inc. (FULC) Have the Potential to Rally 232% as Wall Street Analysts Expect?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q3 2022 Results Conference Call November 8, 2022 8:00 AM ET Company Participants Stephanie Ascher - Stern Investor Relations Bryan Stuart - President and Chief Executive Officer Esther Rajavelu - CFO Paul Bruno - Senior Vice President, Corporate Development Conference Call Participants Dae Gon Ha - Stifel Judah Frommer - Credit Suisse Matt Biegler - Oppenheimer Joseph Schwartz - SVB Leerink Operator Good morning, and welcome to Fulcrum Therapeutics Third Quarter 2022 Conference Call [Operator Instructions]. I would now like to turn the call over to Stephanie Ascher from Stern Investor Relations.

Fulcrum Therapeutics, Inc. (FULC) Q3 2022 Earnings Call Transcript

CAMBRIDGE, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company's 2019 Stock Incentive Plan.

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 19.35% and 45.86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Fulcrum Therapeutics, Inc. (FULC) Reports Q3 Loss, Lags Revenue Estimates

― Selected 12mg as the dose for next cohort in the Phase 1b trial of FTX-6058 in sickle cell disease (SCD) ―

Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results

— Santiago Arroyo, M.D., Ph.D. joined as CMO on November 7, 2022 —

Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer

CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its third quarter 2022 financial results will be released on Tuesday, November 8, 2022 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following upcoming investor conferences:

Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences

Fulcrum Therapeutics, Inc. (FULC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fulcrum Therapeutics, Inc. (FULC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Fulcrum Therapeutics, Inc. (FULC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why Fulcrum Therapeutics, Inc. (FULC) is Poised for a Turnaround After Losing 32.6% in 4 Weeks

- 96-week findings support losmapimod as a disease-modifying therapy for FSHD

Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following upcoming investor conferences:

Fulcrum Therapeutics to Participate at Upcoming September Investor Conferences

CAMBRIDGE, Mass., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Stifel 2022 Biotech Summer Summit, on Wednesday, August 17, 2022 at 11:30 a.m. ET.

Fulcrum Therapeutics® to Participate at the Upcoming Stifel 2022 Biotech Summer Summit

CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the pricing of an underwritten public offering of 9,590,792 shares of its common stock at a public offering price of $7.82 per share. The gross proceeds to Fulcrum from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be $75 million. All shares in the offering are to be sold by Fulcrum. In addition, Fulcrum has granted the underwriters a 30-day option to purchase up to an additional 1,438,618 shares of its common stock. The offering is expected to close on or about August 18, 2022, subject to customary closing conditions.

Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock

Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Stephanie Ascher - Stern, Investor Relations Bryan Stuart - President & Chief Executive Officer Judy Dunn - President, Research & Development Esther Rajavelu - Chief Financial Officer Paul Bruno - Executive Director, Corporate Development Conference Call Participants Judah Frommer - Credit Suisse Ted Tenthoff - Piper Sandler Dae Gon Ha - Stifel Matt Biegler - Oppenheimer Joseph Schwartz - SVB Yatin Suneja - Guggenheim Operator Good morning, and welcome to the Fulcrum Therapeutics Second Quarter 2022 Conference Call. Currently all participants are in a listen-only mode.

Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q2 2022 Results - Earnings Call Transcript

CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today reported financial results for the second quarter of 2022 and announced a strategic plan to realign internal resources to support the two clinical programs that are expected to be the key drivers of near-term value and extend cash runway.

Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its second quarter 2022 financial results will be released on Thursday, August 11, 2022 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Fulcrum Therapeutics® to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 11, 2022 at 8:00 a.m. ET

CAMBRIDGE, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Chief Medical Officer, Christopher Morabito, M.D., will be leaving the company, effective July 13, 2022. Judith Dunn, Ph.D., President of Research and Development will provide interim leadership while the executive search for a new CMO is ongoing.

Fulcrum Therapeutics Announces Departure of Chief Medical Officer

– REACH is the first Phase 3 trial for this rare, progressive, and debilitating muscular disease – – Losmapimod is an oral small molecule that has the potential to be the first therapy to treat FSHD,  the second most common form of muscular dystrophy – – U.S. Food and Drug Administration (FDA) granted Fast Track Designation in 2021 –

Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)

Fulcrum lost hugely this month after announcing data from an early Sickle Cell Disease trial. The other program is also beset with issues.

News for Fulcrum Therapeutics Inc Stock (FULC)